Xuzhou Medical University
2 clinical trials · 2 recruiting · OTHER
Trials by Xuzhou Medical University
RECRUITINGPhase 1 / Phase 2NCT06196255
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis...
Sponsor: Xuzhou Medical UniversityEnrolling: 201 location
Multiple Myeloma
RECRUITINGPhase 1 / Phase 2NCT06759181
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-BCMA/FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A...
Sponsor: Xuzhou Medical UniversityEnrolling: 201 location
Multiple Myeloma